your ip experts in norway · norway, including bergen, trondheim, stavangar and tromsø. in...

Your IP experts in Norway:BiotechnologyLife ScienceChemistryPharmaceuticalChemical Engineering

Introduction 1

Meet the team 4

Hanna Dzieglewska 4

Liz Jones 5

Louise Golding 6

Rebecca Gardner 7

Neil Campbell 8

Philip Webber 9

Deborah Owen 10

Chris Goddard 11

Dan Rowe 12

Phill Price 13

Chris (Kit) Wilkins 14

Adam Yates 15

Mark Scott 15

Case studies 16

About Dehns 20

Contents

Despite being based in

the UK, Dehns is one

of the best known and

most highly regarded

firms of patent

attorneys in Norway,

with a long and proud

history of working

with Norwegian

innovators, dating

back almost 50 years.

1

Dehns currently represents 2 of the 3 Norwegian applicants with the most patent filings over the last 3 years, 6 out of the top 10, and 9 of the top 15.*

We are also proud that in 2019, Dehns filed 3,390 European Patent Applications, more than any other European firm.

However, in addition to working with multinationals, we also work with individual inventors, start-ups, Universities/TTOs and SMEs. This is a diverse group whose needs are not all the same; however, common themes arise again and again: value and cost effectiveness; accessibility and transparency; first rate and pragmatic advice.

Our Biotechnology and Chemical Groups specialise in working for these smaller organisations, helping them build, grow and develop their IP portfolios which in turn adds great value to their businesses.

Dehns' attorneys have numerous clients and have close working relationships with many of the innovation networks and technology incubators in Oslo and the rest of Norway, including Bergen, Trondheim, Stavangar and Tromsø.

In particular, Dehns is heavily involved in the Oslo innovation scene – we normally have attorneys travelling to Oslo to visit clients and prospective clients on a weekly basis. We also host a formal IP clinic (“DehnsDag”) where we offer free IP support and guidance on the first Tuesday of every month at The Science Park (Forskningsparken). We are also members of Norway Health Tech and have a regular presence within Aleap and ShareLab.

Through the provision of these IP clinics, working with start-ups and SMEs over the last 50 years and our involvement with the various incubators and hubs, Dehns’ attorneys have naturally acquired significant hands-on experience with the particular types of issues and concerns start-up and spin-out companies face, leaving them well equipped to provide focused and tailored advice to other such companies.

The remainder of this document highlights senior members of our Biotechnology and Chemical teams who all have experience of working with innovative Norwegian companies in wide variety of technical fields.

Please feel free to contact any of them to discuss how they can support and advise on any of your IP matters.

*2016-2019; source: Patent Pilot

2

Dehns in numbers

Dehns has been working with Norwegian innovators since the early 1970s

Dehns represents 2 out of the top 3, and

9 of the top 15 most

prolific patent application

filers in Norway

60%

Dehns has more than

220 people

220

Dehns filed 3,390 European

Patent Applications

in 2019

3,39033

33 biotechnology and chemistry

experts

3

EDUCATION AND PROFESSIONAL QUALIFICATIONS

BSc Hons (First Class), Biochemistry, Imperial College, 1984

PhD, Biochemistry, University of Kent, 1987

Thesis title: “The enzymatic degradation of bilirubin and its potential use in a clinical diagnostic assay”

Chartered Patent Attorney and European Patent Attorney

Hanna DzieglewskaPartner and Head of Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceHanna has a long history of working with Norwegian clients, starting in her early years with Dynal AS and Nycomed, and for various clients at the University of Oslo, Oslo University Hospital, Sintef,and NTNU. She continues to work with Inven2 AS, NTNU Technology Transfer AS and Sintef TTO, and for Norwegian companies including Algipharma AS and Zelluna AS.

Throughout her time at Dehns, Hanna has worked on a wide range of technologies, but has particular experience in:

• Immunotherapies, including antibodies and antibody-based constructs, adoptive cell transfer, CARs and TCRs

• Nucleic acid based techniques, including diagnostic and other detection assays, amplification and sequencing technologies

• Protein detection assays, including immunoassays

Hanna’s other areas of expertise include:

• Gene expression and protein production

• Therapeutic peptides and proteins, including for cancer or antimicrobial therapy

• Biomarkers and diagnostics

• Alginate-based therapies

Hanna’s work is wide ranging, including working with clients to develop and expand their portfolios, from initial advice and workshops to identify new inventions, drafting and filing patent applications, worldwide patent prosecution and strategy, oppositions, and freedom to operate and infringement and validity advice.

4


BSc, Chemistry and Biochemistry (distinction in Chemistry), University of Cape Town, 1985

BSc (Hons), Biochemistry, University of Cape Town, 1986

MSc, Crystallographic determination of cholic acid:alcohol structures (awarded with Distinction), University of Cape Town, 1989

PhD, Biochemistry, Open University, 1993

Thesis title: “Cell signalling pathways of IL-1 and TNF”


Liz JonesPartner, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceLiz has been working with Norwegian organisations for over 25 years, in many cases helping new companies develop full patent portfolios over many years. Liz regularly travels to Norway to meet clients and has also provided educational content to University clients.

Her Norwegian clients are located throughout Norway, but mostly based in Oslo and Ås and include: PCI Biotech AS, BioCHOS AS, Norwegian University of Life Sciences, Hydrolice AS, GeneSeque AS and XGas AS.

Liz has experience in a wide range of technologies but her specialisms include:

• Molecular biology based inventions, e.g. recombinant products, transgenic plants and animals, genomic therapeutics and diagnostics

• Nucleic acid Sequencing inventions

• Enzymatic degradation of biomass

Other areas of in-depth expertise include:

• Peptide vaccination and use of adjuvants

• Diagnostic detections of SNPs

• Fungicides

• Antibody based inventions

• Photochemical and photodynamic treatments, particularly for cancer treatments

• Treatment of bacteria using bacteriocins or other molecules

• Artificial silk protein production and processing

• Enzyme electrodes

5


MA, Natural Sciences (Chemistry), University of Oxford, 1990


Louise GoldingPartner, Chemical GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceFor the past 30 years, Louise has worked with many different Norwegian clients in various sectors. Back in the early years, Louise worked with Nycomed in handling their ultrasound contrast agent portfolio of cases. Over the years Louise has worked with clients ranging from large corporates such as Equinor Energy AS and Borealis to start-ups, SMEs and University clients. Amongst her University clients are Inven2 and Vestlandets Innovasjonsselskap AS (previously Bergen Tecknologioverføring AS). Louise also currently works with Photocure ASA, PCI Biotech AS, Vitux Group AS, Zeracryl AS, Arctic Pharma AS, Spermatech AS, and OxySolutions AS. Many of Louise’s clients are based at Forskningsparken and she is a regular visitor to Oslo. Louise has also worked with Oslo-based solicitors in advising clients on due diligence matters relating to investments in Norwegian companies.

Louise has experience in a wide range of technologies, but has particular experience in the following areas:

• Pharmaceuticals, in particular novel small molecules and drug re-purposing

• Photodynamic and sonodynamic treatments, particularly for the treatment of cancer

• Nutraceuticals

• Oil and gas technology

Louise also has significant expertise in the following fields:

• Medical diagnostics, including blood glucose sensors for detection and management of diabetes

• Cancer treatments, including improved methods of targeting cancer cells

• Antibacterial agents

• Wound healing treatments

• Polymers for medical use, including stents and nerve grafts

• Treatment and prevention of sea lice infestation in farmed fish

• Materials, including LEDs

Louise’s work involves initial advice on capturing inventions, drafting patent applications and strategic advice relating to worldwide prosecution. She also advises on freedom to operate and validity of third party patents.

6


BSc (Hons), Biochemistry, University of Bristol, 1993


Rebecca GardnerPartner, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceRebecca has been working with Norwegian companies and research organisations for over 20 years. She is regularly in Norway visiting clients based all over the country, from Tromsø and Bodø in the north down to Trondheim, Bergen, Stavanger and Oslo. What began with Alpharma’s collaboration with Tromsø inventors who would go on to form Lytix Biopharma, has developed over the years into a varied practice working closely with TTO’s at some of Norway’s major universities and research organisations, including Norinnova, Vestlandets Innovasjonsselskap (previously Bergen Teknologioverføring) and SINTEF, as well as companies spun-out from these organisations. Working with technology and companies at an early stage means that Rebecca often takes the role of in-house IP advisor, advising on strategy, development of business plans, budgets, transactions and third party rights, as well as developing the patent portfolio.

One recent commercial success story, in which Rebecca was involved with both the original patent drafting and transactional support, was the sale of the Prophylix orphan drugs program to a US company. As well as working with numerous SME’s, including Amicoat, ODI Medical, GOE-IP, Biotec Pharmacon and ArcticZymes, Rebecca also handles cases in the life science field for Equinor.

Rebecca’s technical experience reflects the strengths of research in Norway and a trend towards multi-disciplinary innovation, biology teamed with chemistry, as well as life science based technology which includes medical device, manufacturing and computational elements.

This includes specialisms in:

• Therapeutic peptides and analogues

• Kinase inhibitors

• Aquaculture

Rebecca also has in-depth knowledge of, and expertise in, the following fields:

• Bioprospecting products relating to unique marine proteins and small molecules

• Biotechnology applications within oil and gas

• Nanoparticulate drug delivery systems

• Immunotherapies for cancer

7


BA (First Class), Natural Sciences (Chemistry), University of Oxford, 1995

Part II research into “Approaches to model anomeric amino acid derivatives, possible muscarine analogues”


Neil CampbellPartner, Chemical GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceNeil has worked with Norwegian clients since 1995. Direct clients have included small companies in therapeutic and diagnostic areas, up to multinational chemical giants such Nycomed Imaging AS and Borealis AS. He has also worked with large Norwegian energy companies and Jotun AS. Neil continues to work with the Norwegian University of Science and Technology (NTNU) and various start-up companies associated with NTNU and with the science park in Oslo.

Neil works on a wide range of chemical technologies, but has particular experience in industrial chemistry such as:

• Polymer chemistry such as polyethylene and polypropylene chemistry

• Paint and other protective coatings

• Food technology and nutraceuticals

Neil also has significant expertise in:

• Solid state ceramics

• Pharmaceuticals

• Graphene

Neil’s work is wide ranging and includes initial advice regarding when and how to protect inventions, drafting and filing patent applications, worldwide patent prosecution and strategy, and freedom to operate and validity advice. Neil also has extensive experience in Opposition and Appeal hearings before the EPO, frequently handling 15 or more hearings every year in fields as diverse as polyethylene, chewing gum and paint.

8


MA, Genetics, Cambridge University, UK (1988)

PhD, Molecular Biology, University of Warwick, UK (1993)

Thesis title: "Analysis of the promoter region of the Xenopus N-Cadherin gene"


Philip WebberPartner, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperiencePhilip has been working with Norwegian organisations since 2012, primarily with Vestlandets Innovasjonsselskap AS (VIS, previously known as Bergen Teknologioverføring AS). He generally meets with his Norwegian clients 2-3 times per year (either in Norway or in the UK).

Philip’s work is largely with start-ups, small/medium size companies and universities with inventions in the pharmaceutical or biotechnological fields. He has over 25 years’ experience in dealing with the issues which are important to such entities, such as the financial constraints of start-ups, the need to develop IP strategies for a company’s products and the pressures upon academics to publish their work.

Philip has experience in a wide range of bio-technologies, but his specialisms include:

• Antibodies and antibody-drug conjugates

• Biofermentation and biofuels

• CRISPR/Cas9

• Viral vectors

• Novel genes and proteins

With a strong background in molecular biology, Philip also has expertise in the following areas:

• Biosimilars

• Bioinformatics

• Stem cells

• Diagnostics assays

• Therapeutic treatments

• Virology and vaccines

Philip’s work involves writing and filing patent applications, and getting them granted for his clients all around the world. He has particular expertise in obtaining European patents (including dealing with EPO Opposition and Appeal procedures) and US patents. He also provides advice on IP landscapes and Freedom to Operate (FTO) advice on competitors’ patents.

9


MA, Natural Sciences (Zoology), University of Cambridge, 1992

PhD, University of London (research carried out at the Imperial Cancer Research Fund, London), 1996

Thesis title: “In vitro morphogenesis of human mammary epithelial cells”


Deborah OwenPartner, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceDeborah has been working with Norwegian clients for over 20 years. In the early part of her career at Dehns, Deborah worked with well known Norwegian names such as Dynal and Nycomed, and more recently has also worked with many other organisations in Oslo such as Inven2, Affitech AS, Nextera AS, and many inventors at the University of Oslo and Oslo University Hospital. Deborah plays an active role in supporting the various technology clusters in Oslo, including Aleap, ShareLab, Norway Health Tech and the Oslo Cancer Cluster. Deborah visits Oslo several times a year to meet clients and to hold IP clinics in the Forskningsparken and the Oslo Cancer Cluster.

Throughout her time at Dehns, Deborah has worked on a wide range of technologies, but has particular experience in:

• Immunology, including antibodies and T cells


• Microorganisms, including probiotics

• Screening technologies, including phage display

Other areas of her expertise include:

• Veterinary therapies and animal health

• Therapeutic proteins and peptides

• Recombinant nucleic acids and vectors

• Transgenic plants

• Cancer therapies, including cell therapy

Deborah’s work is wide ranging and includes initial advice regarding when and how to protect inventions, drafting and filing patent applications, patent portfolio development and management, worldwide patent prosecution and strategy, and freedom to operate and validity advice.

10


BA, Natural Sciences (Chemistry), University of Cambridge, 1994

PhD, University of Cambridge, 2000

Thesis Title: “Resin-bound Synthesis and Template-based Chemical Libraries”


Chris GoddardPartner, Chemical GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceChris has worked with Norwegian clients since 2000. Direct clients have included small companies in therapeutic and diagnostic areas, up to multinational pharmaceutical giants. He has also worked with large Norwegian energy companies through Oslo-based IP consultants. Chris has previously worked with companies including Nycomed Imaging, Axis-Shield and Algeta AS, later becoming the primary patent counsel for Axis-Shield and Algeta AS for many years. After working with Algeta for around 14 years, the company was bought by Bayer Pharmaceuticals and Chris continued to work with the Norwegian arm of Bayer for several years.

Chris works on a wide range of chemical technologies, but his particular specialisms include:

• Pharmaceuticals

• Radio-endonuclide therapy

• Pharmaceutical delivery systems

• Diagnostics and assay methods

Chris also has expertise in the following fields:

• Oil well treatment and tracer technologies

• Organic chemistry

• Medical devices

• Solar cells and renewable energy

Having stayed with clients all the way from the start-up stage to big-pharma buyout and licensing, Chris has worked in areas from initial advice and drafting to worldwide patent prosecution, portfolio management, oppositions, appeals, due diligence and out-licensing, as well as advice on freedom to operate and infringement.

11


BSc (Hons) (First Class), Biochemistry, University of Bristol, 1998

PhD, University of Bristol, 2001

Thesis title: “The intracellular mechanisms of thapsigargin-induced inhibition of human vascular smooth muscle cell proliferation”


Dan RoweSenior Associate, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceDan’s experience in assisting Norwegian companies now stretches nearly 20 years. In that time Dan has worked with small biotech start-ups and university spin-outs/technology transfer offices as well as multinational corporations in the Oslo, Trondheim and Bergen areas, helping them protect and exploit their IP and assess their freedom to operate in their chosen fields. He is therefore adept at working closely and effectively with both inventors and management teams, including academic inventors and university technology transfer groups, by understanding and balancing their competing needs and drivers. To this end, he travels to Norway regularly, meeting clients and hosting IP clinics at technology clusters in Oslo, including Aleap and ShareLab.

Dan handles work across the full spectrum of industrial and medical biotechnology. For his Norwegian clients this has seen particular focus on:

• Biomolecular medicine

• Biomolecular diagnostics

• Biomarker-led diagnostics and personalised medicine

Dan also has significant expertise in:

• Small chemical pharmaceuticals

• Advanced drug delivery

• Advanced wound healing products

• Cell-factories for the industrial production of proteins

• Engineered enzymes

• Bioremediation and microbial oil recovery technologies

Dan’s Norwegian clients include AlgiPharma AS, Genetic Analysis AS, Biovotec AS, UniTargeting Research AS, NTNU TTO, Inven2 AS, Vestlandets Innovasjonsselskap AS (VIS, previously known as Bergen Teknologioverføring AS), Biotec Pharmacon ASA, ArcticZymes AS, and Equinor ASA.

12


MBioch, Molecular and Cellular Biochemistry, University of Oxford, 2006


Phill PriceSenior Associate, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperiencePhill has been working with Norwegian clients for almost 15 years, working with many organisations in Oslo and Tromsø such as: Biotec Pharmacon ASA, ArcticZymes AS, Biotec BetaGlucans AS, Hemispherian AS, 3Skin AS, Sana Pharma Group AS, NutraQ AS, SantoSolve AS and MedElle AS.

He visits Oslo several times a year, meeting clients and holding IP clinics in ShareLab, Aleap and Oslo Cancer Cluster.

Throughout his career Phill has worked on a wide range of technologies, but specialises in:

• Diagnostics and biomarkers

• Functional and therapeutic proteins

• Food technology and nutraceuticals (human and animal)

Phill is also highly experienced in:

• Engineered microorganisms and proteins

• Cancer therapies

• Research tools and assay methods

Phill handles all aspects of the patent process from invention capture, drafting applications and guiding applications through examination by Patent Offices worldwide, to providing freedom to operate, infringement and validity advice. He has particular experience in developing IPR portfolios and IP strategies from scratch. He works with both R&D-based companies and scientific service providers with innovative technologies.

13


BSc (Hons), Molecular Biology and Biochemistry, University of Durham, 2000

PhD, Plant Molecular Biology, University of Cambridge, 2004

Thesis title: "Analysis of genes regulating the plant perception of cytokinin"


Chris (Kit) WilkinsSenior Associate, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceKit has been working with Norwegian organisations since he started at Dehns back in 2008. He travels to Norway several times a year, meeting clients and hosting regular IP clinics.

His Norwegian clients are based in Olso, Trondheim and Bergen and include: Aqua Bio Technology, Sintef TTO, Vectron Biosolutions AS, APIM Therapeutics AS, NTNU TTO, Seald AS, Leukolect and Algipharma AS.

Kit has experience in a wide range of technologies but his specialisms include:

• Cosmetic compositions and methods

• Nucleic acid synthesis and detection methods

• Protein production and purification

Other areas of Kit’s expertise include:

• Biosynthetic gene clusters

• Therapeutic peptides and proteins

• Cancer and antimicrobial therapies

Kit’s work includes evaluating inventions for patentability, drafting patent specifications and all aspects of patent prosecution, including worldwide prosecution of patent families. Kit also provides advice on infringement and validity, opposition of granted patents and assistance with the development and management of patent portfolios.

14


BSc (Hons), Biological Sciences, Birmingham University, 2003

PhD, Embryonic Stem Cell Biology, University of Edinburgh, 2007

Thesis title: “Characterisation of the pluripotency determinant Nanog”


Adam YatesAssociate, Biotechnology GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceAdam works with Norwegian clients, including clients based in Oslo (and the surrounding region) and in Tromsø. Adam handles inventions by inventors from Norwegian hospitals and universities, in addition to inventions made in companies. The Norwegian organisations Adam works with include Amicoat AS, Norinnova Technology Transfer AS, Prophylix AS, Hias How2O AS, Affitech AS and Inven2 AS.

Adam works with many technologies, and has particular experience in:

• Antibody-based inventions

• Antimicrobial proteins

• Genetically modified organisms



MChem (First Class), Chemistry, University of Oxford, 2013


Mark ScottAssociate, Chemical GroupT: +44 (0)20 7632 7200 E: [email protected]

Professional ExperienceMark has been working with Norwegian inventors since 2016 and has clients in Trondheim, Tromsø and Bergen. These clients include Pharmasum Therapeutics AS, Vestlandets Innovasjonsselskap AS (VIS, previously known as Bergen Teknologioverføring AS), Universitetet i Tromsø and SINTEF, who he travels to see 2-3 times a year.

He has experience in the following areas:

• Cancer treatments using nanoparticles

• Antimicrobial agents

• Small chemical pharmaceuticals

• Oil well treatment technologies

15

Case studies

16

Case study one

Understanding complex materials to draft patents

Inven2 is the Technology Transfer Office (TTO) for the University of Oslo, and Oslo University Hospital, and with whom Dehns has worked for more than 30 years.

IssueDehns Head of Biotechnology, Hanna Dzieglewska had been approached by Inven2 with a highly complex invention proposal being developed by an inventor at Oslo University Hospital. The invention proposal related to methodology in the preparation of immune cells for adoptive transfer therapy, and in particular, regarding cancer treatments. A patent application for this invention needed to be filed ahead of an imminent conference disclosure.

SolutionHaving reviewed the invention proposal, it was clear that a highly complex invention was involved, requiring background research and a detailed discussion with the inventors, to fully understand the invention, and to place it into context, and consider all possible ramifications and applications of the underlying biological observations. Our initial claim proposals and discussions prompted the inventors further to consider the scope and possible applications of their invention, leading them to expand and develop the inventive concept. The final, iterative, drafting process involved lengthy and very technical discussions with the inventors, and analysis of their data and ideas.

ResultThe patent application was filed ahead of the conference disclosure. Despite this work being completed in a relatively short time frame, the key issue in this case study is that the invention was incredibly technical; Dehns needed to really dig deep and assimilate very complex materials and data to understand and be able to draft a robust set of patent claims.

“Thank you for this huge effort during the last few days. I have been very impressed

by the way you have grasped the overall concept in such a short time and converted

rudimentary feed-back into a fully developed legal text. Beautiful work under stress!”

17

Case study two

Rapid response during a global pandemic

In late March 2020, Dehns was asked by the Head of IPR at a Norwegian TTO to host an online workshop at 24hrs notice with two of their inventors. This related to a new test method for Covid-19, so was extremely urgent.

Following the workshop, new drafts were created within a "very intense" couple of days and applications successfully filed. The client was very pleased with the result and with the service Dehns had been able to provide.

The following is an unsolicited email from the client:

"Thank you for your extremely valuable contribution in this particular case in these

extraordinary times! I have to say... (that) this case in particular shows why we have had such

a long term relationship with you at Dehns.

You always deliver quality, service and what we like to think, personal engagement.

But in this particular case I think you really delivered out of the “Dehns-usual”.

The way you have managed to grasp the inventions and deliver technical contribution,

patent drafts and a final application is impressive.

Again thank you so much. We will keep you up to date with the development of this very exciting technology and the use and spread

of it. Hopefully it will contribute to a world in the need of quality COVID-19 technologies."

18

Directory testimonialsDehns is ranked as a top tier firm by several leading legal and IP directories. Recent quotations from these publications include:

“…the team applies the same high standards to everything it undertakes…”

Chambers UK

“They are renowned in the biotech pharma space and have an international perspective”

Chambers UK

“These attorneys build excellent relationships with clients, are very responsive and

provide commercial advice…”

Chambers UK

“…great for quality of work and are extremely professional…”

Legal 500

“…one of the premier firms for patent work…”

Legal 500

“Diligent service and strong attention to detail”

Managing Intellectual Property

“We use other patent attorney firms but feel that we get a higher value for money from Dehns”

Managing Intellectual Property

19

About Dehns

Dehns is a leading European firm of specialist patent and trade mark attorneys with more than 220 people working across six main offices (London, Munich, Oxford, Brighton, Manchester and Bristol).

Currently in our centenary year, and top tier ranked by all leading IP and legal directories, Dehns provides a comprehensive range of IP services including: patentability assessments, drafting, filing and prosecution, licencing agreements, advice and support on Oppositions and Appeals, Freedom to Operate opinions and IP portfolio strategy advice.

20

We have an outstanding team of 112 patent professionals, 31 of which specialise in the biotechnology, life science, pharmaceutical, chemistry and biochemistry sectors – over 40% of this team have a PhD, highlighting our detailed technical expertise and knowledge in a wide range of fields.

We also have a team of 81 patent professionals who specialise in a comprehensive range of engineering fields, including: physical sciences, photonics, nanotechnology, medical devices, mass spectrometry, electronics and software.

To highlight the strength of our patent business, Dehns has filed the most number of patent applications of any UK firm in each of the last five years and has filed the most European Patent Applications of any European firm in two out of the last four years (2016 and 2019).

Dehns also has a highly successful, top tier ranked trade mark practice, consisting of 11 qualified Trade Mark Attorneys, providing a full range of trade mark services and advice to organisations in numerous sectors.

As evidenced by our consistent top-tier rankings over the years, and the longevity of many of our clients (20, 30 and even 40 years in some cases), Dehns continues to provide the very best quality advice and service delivery, while at the same time being very conscious of clients’ budgetary and time constraints.

In addition, as well as providing a full spectrum of legal services relating to intellectual property, our Innovation Management Group offers consultancy-based services to provide tailored advice for start-up companies.

Please contact us to discuss how Dehns can help and support you through any IP matters, regardless of where you are in your business and IP lifecycle.

Contact DehnsT: +44 (0)20 7632 7200E: [email protected]: www.dehns.com

www.dehns.com

Brighton The Brinell Building 30 Station StreetBrighton BN1 4RBUnited Kingdom

T: +44 (0)1273 244200F: +44 (0)20 7353 8895E: [email protected]

London St Bride’s House10 Salisbury Square London EC4Y 8JDUnited Kingdom

T: +44 (0)20 7632 7200 F: +44 (0)20 7353 8895E: [email protected]

Munich Theresienstraße 6-8 80333 Munich Germany

T: +49 89 2422 8130 F: +49 89 2422 8140E: [email protected]

Oxford Willow CourtWest WayOxford OX2 0JBUnited Kingdom


Manchester Fabric Building 30 Queen Street Manchester M2 5HX United Kingdom

T: +44 (0)161 470 8030F: +44 (0)20 7353 8895E: [email protected]

Bristol10 Victoria Street Bristol BS1 6BN United Kingdom

T: +44 (0)20 7632 7200F: +44 (0)20 7353 8895E: [email protected]

Sandwich Discovery ParkRamsgate RoadSandwich CT13 9FFUnited Kingdom


The information in this document is necessarily of a general nature and is given by way of guidance only; specific legal advice should be sought on any particular matter. While this document has been prepared carefully to ensure that all information is correct at the time of publication, Dehns accepts no responsibility for any damage or loss suffered as a result of any inadvertent inaccuracy. Information contained herein should not, in whole or part, be published, reproduced or referred to without prior approval. Any such reproduction should be credited to Dehns. © Dehns 2020

your ip experts in norway · norway, including bergen, trondheim, stavangar and tromsø. in...

Documents